We present findings on the effect of AMFm on QAACT price, availability, and market share, 6–15 months after the delivery of subsidised ACTs in Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda, and Tanzania (including Zanzibar).
This week I was contacted by Dr. Dana Dalrymple with a very unusual offer. He wishes to provide all MalariaWorld subscribers free access to his book 'Artemisia annua, Artemisinin, ACTs & Malaria Control in Africa' published just seven months ago. This is truly remarkable and we highly appreciate this gesture!
ATP levels and luciferase activity respond rapidly to incubation with anti-malarial drugs and provide quantitative read-outs to detect the appearance and magnitude of drug-induced stress in cultured parasites.
Although ACTs are recommended as first line treatment for uncomplicated malaria, actual use of ACT is very limited, partly due to its high price in pharmacies and retail stores. The Affordable Medicines Facility-malaria (AMFm), a donor-funded global price subsidy, has been proposed as a strategy to increase ACT use in malaria-endemic countries. Given that donor-supported ACT subsidy schemes are costly, it is crucial to ensure that they have their intended impact.